within Pharmacolibrary.Drugs.ATC.N;

model N05BC01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.36666666666666664,
    adminDuration  = 600,
    adminMass      = 0.4,
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0007,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Meprobamate is a carbamate derivative used as an anxiolytic and was historically prescribed for the management of anxiety disorders and short-term relief of anxiety symptoms. Due to concerns over dependence, toxicity, and the introduction of safer alternatives, meprobamate is rarely used or marketed today in most countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for a typical adult based on published ranges in the literature, as no recent or robust source provides a full compartmental PK analysis.</p><h4>References</h4><ol><li><p>Gilbert, JD, et al., &amp; Draffan, GH (1984). The pharmacokinetics of meprobamate following its oral and rectal administration as a series of combinations with diphenhydramine, acetylsalicylic acid, codeine and pentaerythritol tetranitrate. <i>Arzneimittel-Forschung</i> 34(10) 1323–1327. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6549136/&quot;>https://pubmed.ncbi.nlm.nih.gov/6549136</a></p></li><li><p>Coulter, C, et al., &amp; Moore, C (2012). Determination of carisoprodol and meprobamate in oral fluid. <i>Journal of analytical toxicology</i> 36(3) 217–220. DOI:<a href=&quot;https://doi.org/10.1093/jat/bks009&quot;>10.1093/jat/bks009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22417839/&quot;>https://pubmed.ncbi.nlm.nih.gov/22417839</a></p></li><li><p>Simon, S, et al., &amp; Sacks, H (2010). Bioavailability of oral carisoprodol 250 and 350 mg and metabolism to meprobamate: A single-dose crossover study. <i>Current therapeutic research, clinical and experimental</i> 71(1) 50–59. DOI:<a href=&quot;https://doi.org/10.1016/j.curtheres.2010.02.003&quot;>10.1016/j.curtheres.2010.02.003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24683250/&quot;>https://pubmed.ncbi.nlm.nih.gov/24683250</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05BC01;
